Jan 25, 2019 - J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.
Feb 05, 2019 - Sanofi (SNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Feb 05, 2019 - Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
Feb 06, 2019 - Regeneron's (REGN) earnings and sales surpass expectations in Q4 on solid Dupixent and Eylea sales.
Feb 08, 2019 - Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Feb 26, 2019 - Top drug companies addressed sky-high drug prices on Capitol Hill today.
Mar 04, 2019 - The CHMP gives a positive opinion for the label expansion of Regeneron (REGN) and Sanofi's Dupixent for the treatment of asthma in Europe.
Mar 06, 2019 - Pharmaceutical companies are suddenly eager to lower drug prices.
Mar 06, 2019 - Top Stock Reports for Salesforce, Booking Holdings & VMware
Mar 06, 2019 - The FDA accepts Roche's (RHHBY) sNDA for Xofluza to treat influenza in people at high risk of complications.